{"id":54874,"date":"2023-03-15T17:04:26","date_gmt":"2023-03-15T16:04:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/"},"modified":"2023-03-15T17:04:26","modified_gmt":"2023-03-15T16:04:26","slug":"inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/","title":{"rendered":"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nThe AAVenger platform has demonstrated superior lung tropism and transduction efficiency of cells in the upper and lower respiratory tract of the lung, rapid and sustained expression of therapeutic transgenes, and is amenable to repeat dosing.\n<\/li>\n<li>\nInspire\u2019s Business Founders \u2013 C3i Center Inc, Octane Medical Group of Companies, and Ontario Institute for Regenerative Medicine \u2013 are providing investment, corporate development, and commercialization strategy.\n<\/li>\n<\/ul>\n<p>TORONTO&#8211;(BUSINESS WIRE)&#8211;Inspire Biotherapeutics Inc. (\u201cInspire\u201d), an emerging biotech company with a mission to create life-saving gene therapies for monogenic and acquired diseases of the lung, is poised to move its novel lung tropic AAV gene therapy into clinical validation.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230315005700\/en\/1739488\/5\/best_INSPIRE1.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230315005700\/en\/1739488\/21\/best_INSPIRE1.jpg\"><\/a><\/p>\n<p>\nThe AAVenger platform has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. The platform can be applied to treat cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and other monogenic lung diseases.\n<\/p>\n<p>\nInspire\u2019s scientific founders \u2013 Dr. Bernard Th\u00e9baud, chief medical officer, \u2013 a neonatologist and cell therapy pioneer in neonates &#8211; and Dr. Sarah Wootton, chief scientific officer, \u2013 a vectorologist with extensive AAV experience \u2013 say they are pursuing initiation of a first-in-human clinical trial for a lethal neonatal lung disease with short time to data readout and success of therapy.\n<\/p>\n<p>\n\u201cIdentifying vectors that can effectively deliver and express therapeutic transgenes in the lung has been a major challenge in realizing a curative gene therapy for genetic lung diseases,\u201d says Th\u00e9baud, \u201cThe AAVenger platform has demonstrated quick and sustained expression and is amenable to repeated dosing in lung tissue.\u201d\n<\/p>\n<p>\n\u201cInspire\u2019s AAVenger technology is tackling critical unmet need in diseases of the lung,\u201d says Sandra Donaldson, chief executive officer for Inspire. \u201cOur lead indication is currently fatal in neonates \u2013 we are compelled to get this across the finish line! A near-term clinical trial in this fragile population will validate Inspire\u2019s AAVenger platform.\u201d\n<\/p>\n<p>\nThe company launch is supported by three business founders \u2013 C3i Center Inc., Octane Medical Group of Companies, and the Ontario Institute for Regenerative Medicine \u2013 with deep expertise in company creation, translational teams, and regenerative medicine commercialization.\n<\/p>\n<p>\nInspire will be attending the Alliance for Regenerative Medicine\u2019s Cell &amp; Gene Meeting on the Mediterranean April 12-14, 2023, in Barcelona to engage investors and partners in a first-in-human clinical trial in a lethal neonatal lung disease model with short time to data readout and success of therapy.\n<\/p>\n<p>\n<span class=\"bwuline\">About Inspire<\/span>\n<\/p>\n<p>\nInspire\u2019s mission is to create life-saving gene therapies for monogenic and acquired diseases of the lung. Inspire has developed a lung tropic AAV gene therapy platform that has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. Inspire is currently pursing initiation of a First-in-Human clinical trial for a lethal neonatal lung disease with short time to data readout and success of therapy. The platform can apply to cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and other monogenic lung diseases. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.inspirebiotx.com%2F&amp;esheet=53362598&amp;newsitemid=20230315005700&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.inspirebiotx.com%2F&amp;index=1&amp;md5=897c92249872416ab45ca7a0801139e7\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.inspirebiotx.com\/<\/a>\n<\/p>\n<p>\n<span class=\"bwuline\">About C3i Center Inc.<\/span>\n<\/p>\n<p>\nC3i Center Inc. is a leading CDMO offering turnkey services in the development and commercialization of cell and gene therapies, including CRO, biomarker development immune monitoring services to the pharmaceutical and biotechnology industry. In addition, C3i supports Canadian innovations through both cash and in-kind contributions. Founded in 2016, it is based in Montr\u00e9al, Qu\u00e9bec with a satellite office in the MaRS Discovery District in Toronto, Ontario. C3i Laboratories Inc. is based in Laval, Qu\u00e9bec. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcentrec3i.com&amp;esheet=53362598&amp;newsitemid=20230315005700&amp;lan=en-US&amp;anchor=http%3A%2F%2Fcentrec3i.com&amp;index=2&amp;md5=01c999b274f0a58719156af3ab5294c8\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/centrec3i.com<\/a>\n<\/p>\n<p>\n<span class=\"bwuline\">About Octane Medical Group of Companies<\/span>\n<\/p>\n<p>\n<i>Octane<\/i> transforms healthcare with advanced bioprocesses, biomaterials and bioreactors that drive next-generation products in regenerative medicine. One of Octane\u2019s lead technologies, Cocoon\u2122, is a patient-scale cell therapy system that forms the core of a series of versatile cell and tissue therapy production systems. Unlike other bioreactor systems, this platform integrates multiple steps, including upstream and downstream processing. From cell source isolation and cell expansion, through to cell collection, cell washing and final product formation \u2013 all in a closed, single-use disposable cassette. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Foctaneco.com%2F&amp;esheet=53362598&amp;newsitemid=20230315005700&amp;lan=en-US&amp;anchor=https%3A%2F%2Foctaneco.com%2F&amp;index=3&amp;md5=21019741c9042c093b818f1c40ad83bb\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/octaneco.com\/<\/a>\n<\/p>\n<p>\n<span class=\"bwuline\">About Ontario Institute for Regenerative Medicine<\/span>\n<\/p>\n<p>\nThe Ontario Institute for Regenerative Medicine (OIRM) is a non-profit stem cell institute dedicated to transforming discoveries into clinical trials and cures. Through our commitment to collaboration and partnerships, we leverage our resources to fund and support promising advances. OIRM is a passionate champion for investigators and their patients as we build a healthier future for Ontario, Canada, and the world. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Foirm.ca&amp;esheet=53362598&amp;newsitemid=20230315005700&amp;lan=en-US&amp;anchor=https%3A%2F%2Foirm.ca&amp;index=4&amp;md5=7d87a6ebd6cd25463966c6f90a273805\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/oirm.ca<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nFor more information on Inspire, please contact:<br \/>\n<br \/>Sandra Donaldson<br \/>\n<br \/>Chief Executive Officer &amp; Chief Operating Officer<br \/>\n<br \/>Inspire Biotherapeutics Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#x73;&#97;&#x6e;&#x64;&#114;a&#x2e;&#100;o&#x6e;&#x61;&#108;&#x64;&#x73;&#111;n&#x40;&#105;n&#x73;&#x70;&#105;&#x72;&#x65;&#98;i&#x6f;&#116;x&#x2e;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#115;&#x61;&#x6e;d&#114;&#x61;&#46;&#100;&#x6f;&#x6e;&#97;&#x6c;&#x64;s&#111;&#x6e;&#64;&#105;&#x6e;&#x73;&#112;&#x69;&#x72;e&#98;&#x69;o&#116;&#x78;&#x2e;&#99;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The AAVenger platform has demonstrated superior lung tropism and transduction efficiency of cells in the upper and lower respiratory tract of the lung, rapid and sustained expression of therapeutic transgenes, and is amenable to repeat dosing. Inspire\u2019s Business Founders \u2013 C3i Center Inc, Octane Medical Group of Companies, and Ontario Institute for Regenerative Medicine \u2013 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54874","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The AAVenger platform has demonstrated superior lung tropism and transduction efficiency of cells in the upper and lower respiratory tract of the lung, rapid and sustained expression of therapeutic transgenes, and is amenable to repeat dosing. Inspire\u2019s Business Founders \u2013 C3i Center Inc, Octane Medical Group of Companies, and Ontario Institute for Regenerative Medicine \u2013 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T16:04:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230315005700\/en\/1739488\/21\/best_INSPIRE1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform\",\"datePublished\":\"2023-03-15T16:04:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/\"},\"wordCount\":780,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005700\\\/en\\\/1739488\\\/21\\\/best_INSPIRE1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/\",\"name\":\"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005700\\\/en\\\/1739488\\\/21\\\/best_INSPIRE1.jpg\",\"datePublished\":\"2023-03-15T16:04:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005700\\\/en\\\/1739488\\\/21\\\/best_INSPIRE1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005700\\\/en\\\/1739488\\\/21\\\/best_INSPIRE1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/","og_locale":"en_US","og_type":"article","og_title":"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform - Pharma Trend","og_description":"The AAVenger platform has demonstrated superior lung tropism and transduction efficiency of cells in the upper and lower respiratory tract of the lung, rapid and sustained expression of therapeutic transgenes, and is amenable to repeat dosing. Inspire\u2019s Business Founders \u2013 C3i Center Inc, Octane Medical Group of Companies, and Ontario Institute for Regenerative Medicine \u2013 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-15T16:04:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230315005700\/en\/1739488\/21\/best_INSPIRE1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform","datePublished":"2023-03-15T16:04:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/"},"wordCount":780,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230315005700\/en\/1739488\/21\/best_INSPIRE1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/","url":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/","name":"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230315005700\/en\/1739488\/21\/best_INSPIRE1.jpg","datePublished":"2023-03-15T16:04:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230315005700\/en\/1739488\/21\/best_INSPIRE1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230315005700\/en\/1739488\/21\/best_INSPIRE1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/inspire-biotherapeutics-launches-with-pre-seed-investment-to-target-monogenic-and-acquired-lung-diseases-with-proprietary-aavenger-gene-therapy-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54874"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54874\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}